eMedicine Specialties > Pediatrics: General Medicine > Endocrinology

Precocious Puberty: Differential Diagnoses & Workup

Author: Paul B Kaplowitz, MD, PhD, Professor of Pediatrics, George Washington University School of Medicine and Health Sciences; Chief of Endocrinology, Children's National Medical Center
Contributor Information and Disclosures

Updated: Jun 30, 2009

Differential Diagnoses

Precocious Pseudopuberty

Other Problems to Be Considered

Premature pubarche

Premature pubarche refers to the early appearance of pubic hair, axillary hair, or both in boys and girls without other signs of puberty. An adult-type axillary body odor is the other major clinical finding. Signs of severe androgen excess (eg, clitoral enlargement, growth acceleration, acne) should prompt further investigation to exclude a rare virilizing tumor or a variant form of congenital adrenal hyperplasia. The etiology of premature pubarche is an earlier-than-usual increase in the secretion of weak androgens by the adrenal glands (also termed premature adrenarche). Although regulation of adrenal androgen secretion is poorly understood, it is distinct from that of gonadal steroids. Therefore, early appearance of pubic hair may not temporally correlate with appearance of breast development and is generally not a cause for concern. Exposure to exogenous sex hormones is another potential cause of premature pubarche. Children may be inadvertently exposed to androgens through contact with adult males who use topical androgens such as Androgel.

Premature thelarche

Premature thelarche is the appearance of breast development in young girls in the absence of other signs of precocious puberty (eg, growth acceleration, changes in uterine size and vaginal mucosa). Premature thelarche is typically seen in girls aged 3 years or younger. Breast tissue normally seen in the newborn period due to maternal estrogens can persist for a year or more in some infants. The keys to making this diagnosis include the following:

  • Observing that the child is growing in length along her established percentile channel
  • Noting that the amount of breast tissue increases only minimally over time (or may even decrease)
  • Observing a lack of thickening and pigmentation of the nipples and the areola as seen in girls with precocious puberty

The etiology of this condition is unknown. In some cases, small ovarian cysts that transiently produce estrogens may be responsible. In Puerto Rico, an epidemic of premature thelarche in the 1970s was suspected to have been caused by exposure to estrogens in poultry. Despite a lack of firm evidence, phytoestrogens in soy products and other environmental estrogenlike agents (eg, pesticides) have the potential to cause breast development in young children.

Workup

Laboratory Studies

  • Sex steroid levels
    • Measurement of serum testosterone is useful in boys with suspected precocious puberty.
    • Early morning testosterone levels in boys in early puberty are higher than afternoon levels because luteinizing hormone (LH) and testosterone levels rise with sleep onset in early puberty.
    • The stages of puberty as indicated by serum testosterone levels are as follows:
      • Testosterone level less than 30 ng/dL – Generally prepubertal (Depending on the laboratory, testosterone levels of 11-30 ng/dL may represent early puberty)
      • Testosterone level of 30-100 ng/dL – Early pubertal
      • Testosterone level of 100-300 ng/dL – Mid-to-late pubertal
      • Testosterone level of more than 300 ng/dL – Adult
    • For girls, estradiol measurements are less reliable indicators of the stage of puberty. Many commercial assays are not sufficiently specific or sensitive enough to demonstrate an increase during early puberty. levels that exceed 20 pg/mL usually indicate puberty, but some girls who are clearly pubertal may have levels of less than 20 pg/mL. In addition, estradiol levels may fluctuate from week to week. Girls who have ovarian tumors or cysts often have estradiol levels that exceed 100 pg/mL.
    • Levels of adrenal androgens (eg, dehydroepiandrosterone [DHEA], dehydroepiandrosterone sulfate [DHEAS]) are usually elevated in boys and girls with premature pubarche. DHEA-S, the storage form of DHEA, is the preferred steroid to measure because its levels are much higher and vary much less during the day. In most children with premature pubarche, DHEA-S levels are 20-100 mcg/dL, whereas in rare patients with virilizing adrenal tumors, levels may exceed 500 mcg/dL.
    • Consider obtaining a 17-OH serum progesterone study if congenital adrenal hyperplasia is suspected. If a random level is within the reference range, the diagnosis can be excluded; however, if the random 17-OH progesterone level is elevated, an adrenocorticotropic hormone (ACTH) (ie, Cortrosyn) stimulation test provides the greatest diagnostic accuracy.
  • Gonadotropins
    • Because of the development of more sensitive third-generation assays for LH, which can detect levels as low as 0.1 IU/L or lower, the random LH is now the best screening test for central precocious puberty (CPP). The immunochemiluminometric (ICMA) method for LH seems more specific than the immunofluorometric (IFMA) method. An LH level of less than 0.1 IU/L is generally prepubertal, and a recent study suggested an upper reference range limit for LH measured by ICMA of 0.2 IU/L in both boys and girls, with no overlap between prepubertal and pubertal levels in boys and a 10% overlap in girls.13  Random follicle-stimulating hormone (FSH) levels do not discriminate between prepubertal and pubertal children. Suppressed levels of LH and FSH accompanied by highly elevated testosterone or estradiol levels point to precocious pseudopuberty rather than CPP.
    • A definitive diagnosis of CPP may be confirmed by measuring LH and FSH levels 30-60 minutes after stimulation with gonadotropin-releasing hormone (GnRH) at 100 mcg or with a GnRH analog. Because native GnRH is no longer available, most centers are using the analog leuprolide (aqueous form) at a dose of 20 mcg/kg, up to a maximum of 500 mcg. An increase in FSH levels much greater than the increase in LH levels suggests that the child is prepubertal. Some studies suggest that an increase in LH levels to more than 8 IU/L is diagnostic of CPP, but this depends on the specific LH assay used. A study by Carel et al stated that the peak LH level measured by ICMA that defined CPP was 4.1 IU/L in boys and 3.3 IU/L in girls.14 No increase in LH and FSH levels after the infusion of GnRH suggests precocious pseudopuberty.
  • Thyroid: Thyroid tests are not a routine requirement in the evaluation of precocious puberty. Severe hypothyroidism rarely leads to precocious puberty. Major clues of severe hypothyroidism include growth arrest instead of growth acceleration, galactorrhea, and signs of thyroid hormone deficiency.

Imaging Studies

  • Radiography: Radiography of the hand and wrist used to determine bone age is a quick and helpful means to estimate the likelihood of precocious puberty and its speed of progression. If bone age is within one year of chronological age, puberty has not started (eg, a 2-year-old girl with premature thelarche) or the duration of the pubertal process has been relatively brief. If bone age is advanced by 2 years or more, puberty likely has been present for a year or more or is progressing more rapidly.
  • Head MRI
    • MRI may be indicated to look for a tumor or a hamartoma after hormonal studies indicate a diagnosis of CPP. Ask the radiologist to obtain a high-resolution study that focuses on the hypothalamic-pituitary area.
    • For healthy girls aged 6-8 years with no signs or symptoms of CNS disease, the likelihood of finding a tumor or hamartoma is only about 2%; therefore, this test may be unnecessary depending on the clinical situation.
    • The younger the child with CPP, the greater the chance of finding CNS pathology (among children younger than 6 y).
    • For boys younger than 9 years, the incidence of CNS findings is much higher than in girls, and MRI should be part of the evaluation.
  • Pelvic ultrasonography
    • Ultrasonography is unnecessary for girls with a definite diagnosis of CPP. If performed, however, ultrasonography usually reveals bilaterally enlarged ovaries, often with multiple small follicular cysts, and an enlarged uterus with an endometrial stripe.
    • Pelvic ultrasonography is essential when precocious pseudopuberty is suspected in girls (based on examination or hormone levels) because an ovarian tumor or cyst may be detected.

Histologic Findings

  • If CPP is caused by a tumor in the hypothalamic-pituitary area, the histology of the tumor can be important to the patient's prognosis.
  • Gliomas tend to grow more rapidly than astrocytomas, whereas hamartomas are benign.
  • Treatment of precocious puberty associated with a hamartoma suppresses gonadotropin production by the pituitary without effect on the hamartoma itself.
  • For information on different non-CNS tumors associated with precocious puberty see Precocious Pseudopuberty.

More on Precocious Puberty

Overview: Precocious Puberty
Differential Diagnoses & Workup: Precocious Puberty
Treatment & Medication: Precocious Puberty
Follow-up: Precocious Puberty
Multimedia: Precocious Puberty
References

References

  1. Chalumeau M, Chemaitilly W, Trivin C, et al. Central precocious puberty in girls: an evidence-based diagnosis tree to predict central nervous system abnormalities. Pediatrics. Jan 2002;109(1):61-7. [Medline][Full Text].

  2. Ng SM, Kumar Y, Cody D, et al. Cranial MRI scans are indicated in all girls with central precocious puberty. Arch Dis Child. May 2003;88(5):414-8; discussion 414-8. [Medline][Full Text].

  3. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child. Jun 1969;44(235):291-303. [Medline].

  4. Herman-Giddens ME, Slora EJ, Wasserman RC, et al. Secondary sexual characteristics and menses in young girls seen in office practice: a study from the Pediatric Research in Office Settings network. Pediatrics. Apr 1997;99(4):505-12. [Medline][Full Text].

  5. Kaplowitz PB, Oberfield SE. Reexamination of the age limit for defining when puberty is precocious in girls in the United States: implications for evaluation and treatment. Drug and Therapeutics and Executive Committees of the Lawson Wilkins Pediatric Endocrine Society. Pediatrics. Oct 1999;104(4 Pt 1):936-41. [Medline][Full Text].

  6. Parent AS, Teilmann G, Juul A, et al. The timing of normal puberty and the age limits of sexual precocity: variations around the world, secular trends, and changes after migration. Endocr Rev. Oct 2003;24(5):668-93. [Medline][Full Text].

  7. Wu T, Mendola P, Buck GM. Ethnic differences in the presence of secondary sex characteristics and menarche among US girls: the Third National Health and Nutrition Examination Survey, 1988-1994. Pediatrics. Oct 2002;110(4):752-7. [Medline][Full Text].

  8. Bridges NA, Christopher JA, Hindmarsh PC, Brook CG. Sexual precocity: sex incidence and aetiology. Arch Dis Child. Feb 1994;70(2):116-8. [Medline].

  9. de Vries L, Kauschansky A, Shohat M, Phillip M. Familial central precocious puberty suggests autosomal dominant inheritance. J Clin Endocrinol Metab. Apr 2004;89(4):1794-800. [Medline][Full Text].

  10. [Best Evidence] Mamun AA, Hayatbakhsh MR, O'Callaghan M, Williams G, Najman J. Early overweight and pubertal maturation--pathways of association with young adults' overweight: a longitudinal study. Int J Obes (Lond). Jan 2009;33(1):14-20. [Medline].

  11. Frisch RE, McArthur JW. Menstrual cycles: fatness as a determinant of minimum weight for height necessary for their maintenance or onset. Science. Sep 13 1974;185(4155):949-51. [Medline].

  12. Lee JM, Appugliese D, Kaciroti N, et al. Weight status in young girls and the onset of puberty. Pediatrics. Mar 2007;119(3):e624-30. [Medline].

  13. Resende EA, Lara BH, Reis JD, Ferreira BP, Pereira GA, Borges MF. Assessment of basal and gonadotropin-releasing hormone-stimulated gonadotropins by immunochemiluminometric and immunofluorometric assays in normal children. J Clin Endocrinol Metab. Apr 2007;92(4):1424-9. [Medline].

  14. Carel JC, Eugster EA, Rogol A, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics. Apr 2009;123(4):e752-62. [Medline].

  15. Walvoord EC, Mazur T. Behavioral problems and idiopathic central precocious puberty: Fact or fiction?. Pediatr Endocrinol Rev. June 2007;4 (suppl 3):306-12.

  16. Lazar L, Padoa A, Phillip M. Growth pattern and final height after cessation of gonadotropin-suppressive therapy in girls with central sexual precocity. J Clin Endocrinol Metab. Sep 2007;92(9):3483-9. [Medline].

  17. [Guideline] American Academy of Pediatrics. Sexuality education for children and adolescents: Committee on Psychosocial Aspects of Child and Family Health and Committee on Adolescence. Pediatrics. Aug 2001;108(2):498-502.

  18. Badaru A, Wilson DM, Bachrach LK, et al. Sequential comparisons of one-month and three-month depot leuprolide regimens in central precocious puberty. J Clin Endocrinol Metab. May 2006;91(5):1862-7. [Medline].

  19. Carel JC, Lahlou N, Jaramillo O, et al. Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25 mg). J Clin Endocrinol Metab. Sep 2002;87(9):4111-6. [Medline][Full Text].

  20. Eugster EA, Clarke W, Kletter GB, et al. Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial. J Clin Endocrinol Metab. May 2007;92(5):1697-704. [Medline].

  21. Kaplowitz P. Clinical characteristics of 104 children referred for evaluation of precocious puberty. J Clin Endocrinol Metab. Aug 2004;89(8):3644-50. [Medline][Full Text].

  22. Kaplowitz P. Precocious puberty: update on secular trends, definitions, diagnosis, and treatment. Adv Pediatr. 2004;51:37-62. [Medline].

  23. Kaplowitz PB, Slora EJ, Wasserman RC, et al. Earlier onset of puberty in girls: relation to increased body mass index and race. Pediatrics. Aug 2001;108(2):347-53. [Medline][Full Text].

  24. Kletter GB, Kelch RP. Clinical review 60: Effects of gonadotropin-releasing hormone analog therapy on adult stature in precocious puberty. J Clin Endocrinol Metab. Aug 1994;79(2):331-4. [Medline].

  25. Lee PA. Laboratory monitoring of children with precocious puberty. Arch Pediatr Adolesc Med. Apr 1994;148(4):369-76. [Medline].

  26. Neely EK, Wilson DM, Lee PA, et al. Spontaneous serum gonadotropin concentrations in the evaluation of precocious puberty. J Pediatr. Jul 1995;127(1):47-52. [Medline].

  27. Pescovitz OH, Comite F, Hench K, et al. The NIH experience with precocious puberty: diagnostic subgroups and response to short-term luteinizing hormone releasing hormone analogue therapy. J Pediatr. Jan 1986;108(1):47-54. [Medline].

  28. Reiter EO, Saenger P. Premature adrenarche. The Endocrinologist. 1997;7:85-88.

Further Reading

Keywords

precocious puberty, early puberty, central precocious puberty, CPP, premature thelarche, premature pubarche, precocious pseudopuberty, hyperovarianism, early onset of puberty, sexual precocity, precocious puberty, idiopathic CPP, inappropriate sexual behaviors, increased masturbation, short stature, breast enlargement, clitoral enlargement, enlarged testes, congenital adrenal hyperplasia, familial male precocious puberty, Leydig-cell tumors, HCG-secreting tumors, premature adrenarche, increased body fat, astrocytomas, gliomas, germ cell tumors secreting human chorionic gonadotropin, germ cell tumors secreting HCG, hypothalamic hamartomas, hydrocephalus, arachnoid cysts, suprasellar cysts, treatment, diagnosis

Contributor Information and Disclosures

Author

Paul B Kaplowitz, MD, PhD, Professor of Pediatrics, George Washington University School of Medicine and Health Sciences; Chief of Endocrinology, Children's National Medical Center
Paul B Kaplowitz, MD, PhD is a member of the following medical societies: American Academy of Pediatrics, American Diabetes Association, Endocrine Society, and Lawson-Wilkins Pediatric Endocrine Society
Disclosure: Indevus Consulting fee Review panel membership

Medical Editor

Phyllis W Speiser, MD, Chief of Pediatric Endocrinology, Schneider Children's Hospital; Professor of Pediatrics, New York University School of Medicine
Phyllis W Speiser, MD is a member of the following medical societies: American Association of Clinical Endocrinologists, Endocrine Society, Lawson-Wilkins Pediatric Endocrine Society, and Society for Pediatric Research
Disclosure: Nothing to disclose.

Pharmacy Editor

Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine
Disclosure: Pfizer Inc Stock Investment from financial planner; Avanir Pharma Stock Investment from financial planner ; WebMD Salary and stock Employment and investment from financial planner

Managing Editor

Lynne Lipton Levitsky, MD, Chief, Pediatric Endocrine Unit, Massachusetts General Hospital; Associate Professor, Department of Pediatrics, Harvard University Medical School
Lynne Lipton Levitsky, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American Diabetes Association, American Pediatric Society, Endocrine Society, Lawson-Wilkins Pediatric Endocrine Society, and Society for Pediatric Research
Disclosure: Pfizer Grant/research funds P.I.; Tercica Grant/research funds PI, also occasional consultant

CME Editor

Merrily P M Poth, MD, Professor, Department of Pediatrics and Neuroscience, Uniformed Services University of the Health Sciences
Merrily P M Poth, MD is a member of the following medical societies: American Academy of Pediatrics, Endocrine Society, and Lawson-Wilkins Pediatric Endocrine Society
Disclosure: Nothing to disclose.

Chief Editor

Stephen Kemp, MD, PhD, Professor, Department of Pediatrics, Section of Pediatric Endocrinology, University of Arkansas and Arkansas Children's Hospital
Stephen Kemp, MD, PhD is a member of the following medical societies: American Academy of Pediatrics, American Association of Clinical Endocrinologists, American Pediatric Society, Endocrine Society, Phi Beta Kappa, Southern Medical Association, and Southern Society for Pediatric Research
Disclosure: Genentech, Inc. Honoraria Speaking and teaching; Pfizer, Inc. Honoraria Consulting

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.